The administrative and safety monitoring core will support those functions necessary to ensure thesuccessful performance and scientific integration of the three research projects and the six cores, and toprovide independent internal safety monitoring of the three SPOTRIAS projects: The activities of the corewill include: (1) coordination of all activities of the SPOTRIAS project including experimental activities,conferences, and acitivities of the Executive committee; (2) to provide assistance to SPOTRIAS investigatorswith preparation of progress reports, purchasing equipment and supplies, and monitoring financialexpenditures; (3) to maintain close liaison with appropriate administrative bodies at Washington University,including heads of participating Departments (Emergency Medicine, Neurology, Radiology, and NeurologicalSurgery), the Human Studies Committee, the Radioactive Drug Research Committee, and the office of Giftsand Grants; (4) to interact closely with National Institute of Neurological Disorders and Stroke (NINDS) staffand assume responsibility for the preparation of financial, progress, and data safety and monitoringcommittee reports; and (5) to provide independent internal safety monitoring of the three projects andcommunicate directly with the SPOTRIAS data safety and monitoring committee. Colin P. Derdeyn, M.D.,will serve as Director of the Administrative core. He will oversee the financial aspects of the administration ofthe SPOTRIAS project. He will supervise preparation of annual progress reports to the NINDS. He willsupervise the financial support of the projects and cores. He will organize and chair bimonthly meetings ofthe internal SPOTRIAS working group. These meetings will serve as a group forum to monitor progress ofthe projects and performance of the cores. Robert Grubb, Jr.,, M.D., will serve as an internal safety monitorfor the projects. The principal investigators of the projects will be responsible for providing Dr. Grubb with allthe necessary information for him to execute this responsibility. All significant adverse events will bereported to Dr. Grubb. We expect the NIH to appoint a data safety and monitoring committee (DSMB) forProject 2 and Dr. Grubb will report directly to this committee, as well as Lawrence Wechsler, M.D., theexternal safety monitor. Dr. Grubb will also serve as the end-point adjudicator for project 2. He will have theauthority to suspend any project without the consent of the principal investigator
Showing the most recent 10 out of 44 publications
